Search

Your search keyword '"Bizien, Lucy"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Bizien, Lucy" Remove constraint Author: "Bizien, Lucy" Language english Remove constraint Language: english
42 results on '"Bizien, Lucy"'

Search Results

1. Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

2. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency

3. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

4. Neutralizing IFN-[gamma] autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals

5. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia

6. Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child

7. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study

8. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study

9. A sensitive assay for measuring whole-blood responses to type I IFNs.

10. Microglial TNFa controls daily changes in synaptic GABAARs and sleep slow waves.

11. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.

12. Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children

13. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in systemic lupus erythematosus patients with pre-existing autoantibodies neutralising IFN-α

14. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

15. Autoantibodies against type I IFNs in patients with critical influenza pneumonia

16. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

17. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia

18. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

19. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency

20. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.

21. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

22. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

23. Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.

24. SARS-CoV-2 brainstem encephalitis in human inherited DBR1 deficiency.

25. Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease.

26. Microglial TNFα controls daily changes in synaptic GABAARs and sleep slow waves.

27. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.

28. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients.

29. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children.

30. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.

31. Correction: Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.

32. Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

33. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.

34. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.

35. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.

36. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes.

37. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

38. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

39. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.

40. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.

41. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

42. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Catalog

Books, media, physical & digital resources